Clinical data | |
---|---|
ATC code |
|
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.163.818 |
Chemical and physical data | |
Formula | C6H17NO7P2 |
Molar mass | 277.150 g·mol |
3D model (JSmol) | |
SMILES
| |
InChI
| |
(what is this?) (verify) |
Neridronic acid (INN; the anion is called neridronate) is a bisphosphonate. In Italy it is used to treat osteogenesis imperfecta and Paget's disease of bone.
A 2013 clinical trial suggests complex regional pain syndrome type 1 (CRPS) responds to treatment with intravenous neridronate.
References
- Gatti D, Viapiana O, Idolazzi L, Fracassi E, Adami S (2009). "Neridronic acid for the treatment of bone metabolic diseases". Expert Opin Drug Metab Toxicol. 5 (10): 1305–11. doi:10.1517/17425250903029190. PMID 19761412. S2CID 22274296.
- Varenna M, Adami S, Rossini M, et al. (March 2013). "Treatment of complex regional pain syndrome type I with neridronate: a randomized, double-blind, placebo-controlled study". Rheumatology. 52 (3): 534–42. doi:10.1093/rheumatology/kes312. PMID 23204550.
Drugs for treatment of bone diseases (M05) | |
---|---|
Bisphosphonates | |
Bone morphogenetic proteins | |
Other |
|
This drug article relating to the musculoskeletal system is a stub. You can help Misplaced Pages by expanding it. |